112
Germany-based biotech company, CatalYm, has closed an oversubscribed US$150m Series D financing. Founded in 2016 with support from Forbion and BGV, CatalYm is a leader in the development in a new class of cancer treatments aiming to prevent or reverse cancer resistance to checkpoint inhibition, chemotherapy and other targeted treatments.
The firm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumours. GDF-15, an immunosuppressant important for…